Steroid-Modified Tinea in India: The Silent Epidemic Every Doctor Should Understand
🩺 CLINICAL DERMATOLOGY MGA Clinical Education Series · 8 min read A patient walks into your OPD with a widespread, pale, mildly itchy skin rash on the trunk and groin. He has seen a pharmacist, used a cream, felt better for a week — and now it is back, larger and harder to define. This scenario plays out in dermatology OPDs and general physician clinics across India every single day. The culprit, in many of these cases, is not a new or unusual pathogen. It is an old fungal infection that has been allowed to change its face — because of a tube of OTC cream. This article explains what steroid-modified tinea is, why India is at the centre of a documented dermatology crisis, how these altered infections present clinically, why they are harder to clear, and what the published evidence says every treating doctor should do differently. 🔍 Quick Reference Condition: Steroid-modified tinea / Tinea incognito Cause: OTC topical steroid (or steroid–antifungal–antibiotic triple combination) applied to an undiagnosed dermatophyte infection Effect: Atypical clinical appearance, missed diagnosis, wider spread, treatment resistance Key Indian literature: IJDVL — Verma, Panda et al. 2021 (3-part series); IADVL–ITART Consensus 2020; Dutta, Rasul & Boro, IJDVL 2017 Doctor’s role: Clinical recognition, KOH confirmation, patient education, pharmacist communication 🔬 What Is Steroid-Modified Tinea (Tinea Incognito)? Tinea incognito — now more accurately called steroid-modified tinea in Indian clinical literature — refers to a dermatophyte infection whose typical clinical appearance has been altered by the application of a topical corticosteroid (or a calcineurin inhibitor). The term was first reported in 1968 by British dermatologists Dr Adrian Ive and Dr Ronnie Marks, who described patients with fungal infections masked by topical steroid use presenting as seborrheic dermatitis, eczema, or psoriasis-like eruptions. The mechanism is well understood: topical corticosteroids suppress local skin immunity — specifically, they downregulate antigen-presenting cell function, reduce IL-12 and Th1 activation, and shift the immune response toward a Th2 profile. The dermatophyte encounters a local immune environment that has been instructed to stand down. The inflammation that normally produces the classic raised, scaly, well-defined ring fades. The infection spreads laterally and sometimes deeper, but looks far less angry than it should. As published in Journal of Clinical Medicine (Zacharopoulou et al., 2024, PMC11172699), the more topical steroid that is applied, the more extensive and unrecognisable the fungal infection becomes. A critical nuance noted by Verma SB and colleagues in IJDVL (2021, doi: 10.25259/IJDVL_301_20) is that in the Indian epidemic, a strict “tinea incognito” — where the infection is completely unrecognisable — is less common than steroid-modified tinea, where an active border is often still visible despite morphological distortion. The IJDVL authors argue that “steroid-modified tinea” is therefore the more accurate term for the majority of Indian cases. 🏥 How an OTC Cream Habit Became a National Dermatology Concern India’s climate — high humidity, high ambient temperature across much of the country, and monsoon seasons that last months — creates conditions strongly favourable to dermatophyte growth and spread. Tinea corporis, tinea cruris, and tinea faciei are among the most common superficial infections seen in both urban and rural OPDs. In this environment, an itchy circular rash is a predictably common presentation. The problem is what happens next. Fixed-dose combination (FDC) creams containing a potent topical corticosteroid (typically clobetasol propionate or betamethasone dipropionate), an antifungal agent, and an antibacterial agent are widely available over the counter in India. Research published in the Indian Journal of Dermatology, Venereology and Leprology (Dutta, Rasul & Boro, IJDVL 2017) found that pharmacists were responsible for recommending these combination creams in the majority of tinea incognito cases — 78% of patients in that study were using products recommended by a pharmacist. Patients used these preparations for durations ranging from six weeks to twelve years without medical supervision. Why do patients keep using them? The steroid component produces rapid, visible relief within a few days. Itch decreases, redness fades. Patients interpret this as a cure. When the cream is stopped, the itch returns worse than before — because the fungus has been spreading unchecked beneath a suppressed immune response. The patient reaches for the tube again. The cycle repeats. A landmark 2021 three-part IJDVL series by Verma SB, Panda S, Nenoff P and colleagues described the situation as an “unprecedented epidemic-like scenario” of dermatophytosis in India, attributing the crisis directly to indiscriminate use of FDC corticosteroid creams and the emergence of a novel, partially terbinafine-resistant species — Trichophyton indotineae (formerly classified as T. mentagrophytes ITS genotype VIII) — which the WHO Fungal Priority Pathogens List (2022) has since acknowledged as a global concern. 📊 What the Published Research Documents • The prevalence of superficial dermatophytosis in different regions of India ranges from 36.6% to 78.4% — a range described by experts as constituting a national epidemic (topical antifungal-corticosteroid FDC review, Indian Journal of Pharmacology). • A cost-of-illness analysis published in Clinical and Experimental Dermatology (Jagadeesan et al., 2023) found that patients using topical steroids for dermatophytosis in India incur approximately 40% higher treatment costs than steroid-naive cases. • The IADVL Task Force Against Recalcitrant Tinea (ITART) Consensus 2020 noted a six- to seven-year pattern of unprecedented increase in recurrent, chronic, and steroid-modified dermatophytosis involving glabrous skin. • A study from Western Uttar Pradesh (Thakur et al., Journal of Dermatology and Cosmetology, 2018) conducted across 100 steroid-modified tinea cases identified lack of qualified dermatologists in rural areas as a compounding factor — a gap that directly increases irrational corticosteroid use. 👁️ Clinical Recognition: How Steroid-Modified Tinea Presents Differently The diagnostic challenge is that steroid-modified tinea no longer looks like textbook ringworm. The classic well-defined, raised, scaly, erythematous ring with central clearing is modified or absent. Recognising the altered patterns is the first clinical skill every doctor managing skin conditions in India needs to develop. Feature Classic Tinea (Untreated) Steroid-Modified Tinea Border Well-defined, raised, scaly Blurred, less elevated, less scaly Central clearing Present (classic ring shape) Often absent — study data shows 94.1% of steroid-modified

